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Background
Second-generation (atypical) antipsychotic drugs are widely used to treat psychosis, 
aggression, and agitation in patients with Alzheimer’s disease, but their benefits 
are uncertain and concerns about safety have emerged. We assessed the effective-
ness of atypical antipsychotic drugs in outpatients with Alzheimer’s disease.
Methods
In this 42-site, double-blind, placebo-controlled trial, 421 outpatients with Alzhei-
mer’s disease and psychosis, aggression, or agitation were randomly assigned to re-
ceive olanzapine (mean dose, 5.5 mg per day), quetiapine (mean dose, 56.5 mg per 
day), risperidone (mean dose, 1.0 mg per day), or placebo. Doses were adjusted as 
needed, and patients were followed for up to 36 weeks. The main outcomes were 
the time from initial treatment to the discontinuation of treatment for any reason 
and the number of patients with at least minimal improvement on the Clinical 
Global Impression of Change (CGIC) scale at 12 weeks.
Results
There were no significant differences among treatments with regard to the time to 
the discontinuation of treatment for any reason: olanzapine (median, 8.1 weeks), 
quetiapine (median, 5.3 weeks), risperidone (median, 7.4 weeks), and placebo (median, 
8.0 weeks) (P = 0.52). The median time to the discontinuation of treatment due to a 
lack of efficacy favored olanzapine (22.1 weeks) and risperidone (26.7 weeks) as 
compared with quetiapine (9.1 weeks) and placebo (9.0 weeks) (P = 0.002). The time 
to the discontinuation of treatment due to adverse events or intolerability favored 
placebo. Overall, 24% of patients who received olanzapine, 16% of patients who re-
ceived quetiapine, 18% of patients who received risperidone, and 5% of patients who 
received placebo discontinued their assigned treatment owing to intolerability 
(P = 0.009). No significant differences were noted among the groups with regard to 
improvement on the CGIC scale. Improvement was observed in 32% of patients as-
signed to olanzapine, 26% of patients assigned to quetiapine, 29% of patients as-
signed to risperidone, and 21% of patients assigned to placebo (P = 0.22).
Conclusions
Adverse effects offset advantages in the efficacy of atypical antipsychotic drugs for 
the treatment of psychosis, aggression, or agitation in patients with Alzheimer’s dis-
ease. (ClinicalTrials.gov number, NCT00015548.)
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Delusions, hallucinations, aggres-sion, and agitation affect more than half of patients with Alzheimer’s disease and 
related dementias.1-4 Antipsychotic drugs are used 
to treat these behaviors and symptoms and are 
among the most frequently used psychotropic drugs 
in Alzheimer’s disease.5,6
Second-generation (atypical) antipsychotic 
drugs have been considered to be at least as ef-
fective as conventional antipsychotic agents such 
as haloperidol, with a lower risk of most adverse 
effects,7 and are used as first-line pharmacologic 
treatments for patients with dementia.5,8 How-
ever, there is a dearth of placebo-controlled and 
active-drug–controlled, randomized trials and lon-
ger-term data from controlled trials regarding 
the effectiveness of atypical antipsychotic drugs. 
Moreover, the available data on efficacy have been 
inconsistent, rates of response to placebo have 
been high, and patients have been required to re-
ceive drugs for the 6-week to 12-week study pe-
riods, whether or not they benefited, an artificial 
situation that does not address effectiveness.9
New safety issues have emerged with respect 
to atypical antipsychotic drugs. Increased risks 
of cerebrovascular adverse events10-12 and death13,14 
have complicated their use. Antidepressant med-
ications such as citalopram have been suggest-
ed as alternatives to antipsychotic drugs,15 at least 
for aggression or agitation,16 despite the lack of 
data from adequate trials.17
We conducted a double-blind, placebo-con-
trolled trial to determine the effectiveness of olan-
zapine, quetiapine, and risperidone as compared 
with placebo in outpatients with Alzheimer’s dis-
ease and psychosis, aggression, or agitation.
Me thods
Study Setting and Design
The trial was part of the National Institute of 
Mental Health (NIMH) Clinical Antipsychotic 
Trials of Intervention Effectiveness. Such trials 
address broad outcomes in settings and with in-
terventions that reflect usual practices. The ra-
tionale, design, and methods of this study — 
Clinical Antipsychotic Trials of Intervention 
Effectiveness–Alzheimer’s Disease (CATIE-AD) 
— have been described previously.18 The trial was 
conducted between April 2001 and November 
2004 at 45 sites in the United States (26 univer-
sity clinics, 7 Veterans Affairs medical centers, 
and 12 private-practice sites [3 sites did not ran-
domly assign any patients]).
In phase 1 of the study, patients were randomly 
assigned under double-blind conditions to receive 
olanzapine, quetiapine, risperidone, or placebo in 
a 2:2:2:3 ratio. Doses were adjusted as clinically 
indicated by study physicians. If the physicians 
judged that the patient’s response was not ade-
quate at any time after the first 2 weeks, then treat-
ment could be discontinued. Patients with an ad-
equate response continued treatment for up to 
36 weeks. Patients whose initial treatment was 
discontinued during phase 1 could be enrolled in 
phase 2 and randomly assigned under double-
blind conditions to receive one of the antipsy-
chotic drugs to which they were not initially as-
signed or to receive citalopram.18 This report is 
limited to phase 1 results.
Participants
Eligible participants fulfilled criteria for demen-
tia of the Alzheimer’s type (according to the Diag-
nostic and Statistical Manual of Mental Disorders, fourth 
edition)19 or probable Alzheimer’s disease20 on the 
basis of the history, physical examination, results 
of structural brain imaging, and the score on the 
Mini–Mental State Examination (MMSE)21; the 
MMSE score had to be between 5 and 26 (on a 
scale from 0 to 30, with lower scores indicating 
poorer performance). To be eligible, patients had 
to be ambulatory and living at home or in an as-
sisted-living facility. Eligible patients had delu-
sions, hallucinations, aggression, or agitation that 
developed after the onset of dementia and was 
severe enough to disrupt their functioning and, in 
the opinion of the study physicians, to justify treat-
ment with antipsychotic drugs. Signs and symp-
toms of psychosis, aggression, or agitation had to 
have occurred nearly daily during the previous 
week or at least intermittently for 4 weeks. During 
the week before they were randomly assigned to 
treatment, eligible patients also had a severity 
rating of at least “moderate” for conceptual dis-
organization, suspiciousness, or hallucinatory 
behavior on the Brief Psychiatric Rating Scale 
(BPRS).22 Alternatively, a frequency rating of “of-
ten” or “more frequently” and a severity rating 
of at least “moderate” were required for delusions, 
hallucinations, agitation, or “aberrant motor 
behavior” in the Neuropsychiatric Inventory.23 
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A study partner or caregiver who had regular 
contact with the patient was required to partici-
pate in the assessments.18
Patients were excluded if they had received a 
diagnosis of a primary psychotic disorder (e.g., 
schizophrenia), delirium, other dementia such as 
vascular dementia24 or Lewy-body dementia,25 or 
psychosis, agitation, or aggression that could be 
better accounted for by another medical condition, 
medication, or substance abuse. Patients were also 
excluded if they required psychiatric admission, 
were suicidal, were going to receive treatment with 
a cholinesterase inhibitor or antidepressant medi-
cation, had previously been treated with two of the 
three atypical antipsychotic drugs under study, or 
had contraindications to any of the study drugs.
The study was approved by the NIMH data 
and safety monitoring board and by the institu-
tional review board at each site. Written informed 
consent was obtained from the patients or their 
legally authorized representatives and from the 
partners or caregivers who participated with the 
patients.
Interventions
The trial design encouraged prescribing that re-
f lected clinical practice while maintaining the 
randomized and double-blind treatment assign-
ment. The study physicians determined the start-
ing doses and adjusted the doses on the basis of 
their clinical judgment and patients’ responses. 
Medications were dispensed at each visit in the 
form of identically appearing small and large cap-
sules containing lower and higher doses of olan-
zapine (Zyprexa, Eli Lilly; 2.5 mg or 5.0 mg), que-
tiapine (Seroquel, AstraZeneca; 25 mg or 50 mg), 
risperidone (Risperdal, Janssen Pharmaceutica; 
0.5 mg or 1.0 mg), or placebo.
To treat difficult behaviors during the trial, 





50 Did not meet inclusion criteria
14 Declined to participate
36 Were excluded for other reasons
94 Assigned to quetiapine
0 Did not take drug
77 Discontinued phase 1
50 For lack of efficacy
15 For intolerability
12 For other reasons
17 Completed phase 1
54 Entered phase 2
23 Did not enter phase 2
85 Assigned to risperidone
1 Did not take drug
66 Discontinued phase 1
37 For lack of efficacy
15 For intolerability
14 For other reasons
19 Completed phase 1
49 Entered phase 2
17 Did not enter phase 2
100 Assigned to olanzapine
1 Did not take drug
80 Discontinued phase 1
39 For lack of efficacy
24 For intolerability
17 For other reasons
20 Completed phase 1
57 Entered phase 2
23 Did not enter phase 2
142 Assigned to placebo
3 Did not take drug
121 Discontinued phase 1
97 For lack of efficacy
7 For intolerability
17 For other reasons
21 Completed phase 1
93 Entered phase 2
28 Did not enter phase 2
Figure 1. Enrollment and Outcomes. 
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study medication or prescribe a benzodiazepine or 
oral or parenteral haloperidol.
All patients and caregivers were given basic 
information about Alzheimer’s disease.26 Caregiv-
ers were offered two counseling sessions during 
the first 18 weeks and could speak with staff mem-
bers as needed.
Outcomes
The primary outcome measure was the time until 
discontinuation of treatment for any reason in 
phase 1. This outcome integrates the judgments 
of patients, caregivers, and clinicians regarding ef-
ficacy, safety, and tolerability into a global measure 
of effectiveness that reflects therapeutic benefits 
in relation to undesirable effects.
The two primary hypotheses in phase 1 were, 
first, there would be pairwise differences between 
the three groups given atypical antipsychotic agents 
and the placebo group in the time until discon-
tinuation of treatment for any reason, and second, 
that among those antipsychotic drugs that were 
found to be different from placebo, none would be 
inferior to the others.
The main secondary outcome measure was 
the attainment of minimal or greater improve-
ment on the Clinical Global Impression of Change 
(CGIC)27 scale at week 12 while the patients con-
tinued to receive the phase 1 drug. The other sec-
ondary outcomes were the time to the discontinu-
ation of treatment in phase 1 because of lack of 
efficacy and the time to the discontinuation of 
treatment because of adverse events, intolerability, 
or death. Safety was assessed by eliciting infor-
mation about the occurrence of adverse events. 
The patients’ weight and prolactin, glucose, cho-
lesterol, and triglyceride levels were measured at 
weeks 12, 24, and 36.
Statistical Analysis
Patients who underwent randomization and re-
ceived at least one dose of the study medication 
were included in the intention-to-treat sample. 
Randomization was performed with the use of 
permuted blocks of nine per site without stratifi-
cation and was implemented with the use of an 
interactive voice-response telephone system.
A total of 421 patients underwent randomiza-













Age — yr 78.8±7.3 77.3±8.7 78.4±7.1 77.3±7.1 77.9±7.5
Female sex — no. (%) 55 (55) 50 (53) 49 (58) 81 (57) 235 (56)
Race — no./total no. (%)†
White 80/99 (81) 76/94 (81) 68/85 (80) 107/141 (76) 331/419 (79)
Black 14/99 (14) 15/94 (16) 15/85 (18) 31/141 (22) 75/419 (18)
Other 5/99 (5) 3/94 (3) 2/85 (2) 3/141 (2) 13/419 (3)
Education — no. (%)
Did not complete high school 28 (28) 21 (22) 15 (18) 37 (26) 101 (24)
General equivalency diploma or high-
school diploma
35 (35) 33 (35) 28 (33) 46 (32) 142 (34)
<4 yr of college 16 (16) 16 (17) 22 (26) 36 (25) 90 (21)
≥4 yr of college 15 (15) 21 (22) 17 (20) 20 (14) 73 (17)
Unknown 6 (6) 3 (3) 3 (4) 3 (2) 15 (4)
Married — no. (%) 63 (63) 56 (60) 49 (58) 81 (57) 249 (59)
Residence — no. (%)
Own home 77 (77) 69 (73) 61 (72) 100 (70) 307 (73)
Family’s home 11 (11) 13 (14) 14 (16) 28 (20) 66 (16)
Assisted-living facility 9 (9) 10 (11) 10 (12) 12 (8) 41 (10)
Other 3 (3) 2 (2) 0 2 (1) 7 (2)
atypical antipsychotic drugs in alzheimer’s disease
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tion (from a target sample of 450 patients), yield-
ing a statistical power of 99% to identify a differ-
ence of 33% in the rates of discontinuation of 
treatment by 36 weeks between any one of the 
drugs and placebo and a power of 80% to detect 
a difference of 20%, assuming a 60% rate of dis-
continuation in the placebo group.
We used Kaplan–Meier survival curves to esti-
mate the time to the discontinuation of treatment 
for all patients in the intention-to-treat population. 
The treatment groups were compared with the 
use of Cox proportional-hazards regression mod-
els,28 stratified according to site. Sites with 17 or 
fewer patients were grouped according to the size 
and type of site (i.e., university clinic, private prac-
tice, or Veterans Affairs medical center) for a total 
of 15 sites (8 pooled and 7 with 18 or more ran-
domly assigned patients).
In the Cox model, the overall difference among 
the treatment groups was evaluated with the use 
of a test with 3 degrees of freedom. If the differ-
ence was significant at a P value of less than 0.05, 
then each drug was compared with placebo by 
means of a Hochberg adjustment for multiple 
comparisons.29














MMSE total score 15.0±5.4 14.9±6.1 15.7±6.1 14.7±5.8 15.0±5.8
Alzheimer’s Disease Assessment Scale (cogni-
tive) total score
34.6±12.7 36.1±13.6 31.1±13.6 35.7±13.2 34.6±13.3
Criteria met for psychosis of Alzheimer’s dis-
ease — no./total no. (%)
73/100 (73) 73/93 (79) 71/85 (84) 106/142 (75) 323/420 (77)
BPRS total score 27.0±11.8 28.0±12.3 27.7±13.6 28.2±12.0 27.8±12.3
NPI total score‡ 31.8±16.3 37.6±18.4 38.3±20.2 39.1±17.8 36.9±18.3 
Delusions  — no./total no. (%) 77/98 (79) 76/93 (82) 74/84 (88) 112/140 (80) 339/415 (82)
Hallucinations — no./total no. (%) 41/98 (42) 47/93 (51) 47/83 (57) 67/139 (48) 202/413 (49)
Agitation or aggression — no./total no. (%) 82/98 (84) 80/93 (86) 71/83 (86) 125/140 (89) 358/414 (86)
Depression — no./total no. (%) 55/98 (56) 58/93 (62) 51/83 (61) 88/140 (63) 252/414 (61)
Alzheimer’s Disease Cooperative Study– 
Activities of Daily Living Inventory
39.4±17.4 39.0±17.8 40.0±18.1 38.2±16.3 39.0±17.2
Medications — no. (%)§
Antidepressant or antipsychotic 27 (27) 19 (20) 23 (27) 35 (25) 104 (25)
Antidepressant 19 (19) 9 (10) 18 (21) 18 (13) 64 (15)
Conventional antipsychotic 5 (5) 7 (7) 1 (1) 6 (4) 19 (5)
Atypical antipsychotic 11 (11) 7 (7) 10 (12) 16 (11) 44 (10)
Cholinesterase inhibitor 67 (67) 54 (57) 50 (59) 82 (58) 253 (60)
Mean weight — lb¶ 148.9±36.6 153.3±30.5 151.7±31.4 148.3±28.0 150.3±31.4
Mean body-mass index∥ 25.3±5.7 25.5±3.9 25.9±4.8 25.2±4.0 25.4±4.6
* Plus–minus values are means ±SD. MMSE scores range from 0 to 30, with higher scores indicating better mental status; scores on the
Alzheimer’s Disease Assessment Scale range from 0 to 70, with lower scores indicating milder disease; BPRS scores range from 0 to 108,
with lower scores indicating milder symptoms; scores on the Neuropsychiatric Inventory (NPI) range from 0 to 144, with lower scores indi-
cating milder symptoms; and scores on the Alzheimer’s Disease Cooperative Study–Activities of Daily Living Inventory range from 0 to 78,
with higher scores indicating better functioning. Because of rounding, percentages may not total 100. Treatment groups were compared 
for baseline differences with the use of analysis of variance or chi-square tests.
† Race was reported by the patient or caregiver. “Other” includes Native American or Native Alaskan (<1% of patients), Asian (2%), Native 
Hawaiian or other Pacific Islander (<1%), and more than one race (2%).
‡ P = 0.02 for the overall comparison of the treatment groups.
§ Trazodone accounted for 47% of antidepressant use, and donepezil accounted for 72% of cholinesterase-inhibitor use.
¶ To convert values to kilograms, divide by 2.2.
∥ The body-mass index is the weight in kilograms divided by the square of the height in meters.
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cantly better than placebo was then tested for 
noninferiority to the other antipsychotic agents. 
Noninferiority was concluded when the P value 
was less than 0.025 from a one-sided test with a 
margin of 2.0 (i.e., the upper limit of the 95% con-
fidence interval [CI] for the hazard ratio was <2.0). 
Two atypical antipsychotic drugs were considered 
to be equivalent if the CI was contained within 
0.5 and 2.0 (i.e., each drug was noninferior to the 
other); this was a broad equivalence margin for 
noninferiority.
Finally, any antipsychotic drug found to be non-














Initial dose — mg per day
Mean 3.2 34.1 0.7
Range 0–10 0–100 0.5–2.5
Last dose — mg per day
Mean 5.5 56.5 1.0
Range 0–17.5 0–200 0–2.0
Discontinuation of treatment for any reason 
— no. of patients (%)
79 (80) 77 (82) 65 (77) 118 (85)
Kaplan–Meier estimate of time to 
discontinuation — wk
0.52†
50th percentile 8.1 5.3 7.4 8.0
95% CI 5.1–11.6 3.6–8.1 5.0–12.0 5.0–9.3
Comparison with placebo
Hazard ratio 0.83 1.01 0.88 —
95% CI† 0.62–1.11 0.75–1.36 0.64–1.20
P value for test of a difference 0.21 0.95 0.41
Discontinuation of treatment because 
of lack of efficacy — no. 
of patients (%)
39 (39) 50 (53) 37 (44) 97 (70)
Kaplan–Meier estimate of time to dis-
continuation — wk
0.002†
50th percentile 22.1 9.1 26.7 9.0
95% CI 12.1–?‡ 7.0–21.6 8.1–?‡ 6.4–11.6
Comparison with placebo
Hazard ratio 0.51 0.81 0.61
95% CI 0.35–0.74 0.57–1.15 0.41–0.89
P value for test of a difference <0.001§ 0.24 0.01§
Comparison with quetiapine
Hazard ratio 0.63 0.75
95% CI 0.41–0.96 0.49–1.16
P value for test of superiority¶ 0.02∥ 0.10
Comparison of olanzapine with ris peridone
Hazard ratio 0.84
95% CI 0.53–1.32
P value for test of noninferiority
Olanzapine vs. risperidone  <0.001∥
Risperidone vs. olanzapine 0.01∥
atypical antipsychotic drugs in alzheimer’s disease
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Table 2. (Continued.)












Discontinuation of treatment because of intol-
erability, adverse events, or 
death — no. of patients (%)
24 (24) 15 (16) 15 (18) 7 (5)
Kaplan–Meier estimate of time to dis-
continuation — wk**
0.009†
25th percentile 13.7 29.4 20.1 ?
95% CI 6.1–? 5.6–? 9.6–? ?–?
Comparison with placebo
Hazard ratio 4.32 3.58 3.62
95% CI 1.84–10.12 1.44–8.91 1.45–9.04
P value for test of a difference <0.001§ 0.006§ 0.006§
Comparison with quetiapine
Hazard ratio 1.21 1.01
95% CI 0.62–2.36 0.49–2.11








Comparison of olanzapine with risperidone
Hazard ratio 1.19
95% CI 0.61–2.32




Response based on CGIC score at 12 wk 
— no. of patients (%)†† 
32 (32) 24 (26) 24 (29) 29 (21) 0.22
Comparison with placebo P = 0.05 P = 0.37 P = 0.21
Change in score at 12 wk — change 
(no. of patients)‡‡
CGIC§§ 2.9±1.3 (40) 2.7±1.1 (31) 2.6±1.5 (33) 3.3±1.5 (48)
BPRS total score −7.4±9.8 (40) −7.4±9.8 (30) −8.5±12.2 (32) −3.9±9.8 (48)
NPI total score −14.0±18.7 (40) −16.6±18.3 (31) −16.4±15.0 (32) −9.0±20.6 (47)
* Plus–minus values are means ±SD. Question marks denote 95% CI limits that could not be estimated because of low event rates.
†  Hazard ratios are based on a Cox proportional-hazards regression model. The P value for the overall treatment group comparison is from a
test with 3 degrees of freedom. A ratio of less than 1 indicates a longer time to the discontinuation of the first treatment listed. A 95% CI be-
tween 0.5 and 2.0 indicates equivalence of treatments. A test of noninferiority compares the upper limit of the 95% CIs with 2.0. A test of 
superiority compares the upper limit of the 95% CI with 1.0.
‡  The upper confidence limit of the Kaplan–Meier 50th percentile for discontinuation of treatment because of lack of efficacy could not be 
estimated because of low event rates in the olanzapine and risperidone groups.
§ The P value for comparison with placebo is significant at 0.05 in accordance with the Hochberg adjustment for multiple comparisons.
¶  Olanzapine and risperidone were both noninferior to quetiapine (P<0.001).
∥  The P value, which is significant at 0.025, is applicable to one-sided tests of noninferiority or superiority.
** The Kaplan–Meier 25th percentile for discontinuation of treatment owing to adverse events, intolerable side effects, or death could not be
estimated in the placebo group because of low event rates. The upper confidence limit of the active-treatment groups could not be calcu-
lated because of low event rates in the placebo group.
†† A response was defined as continued treatment with the original phase 1 study drug and at least minimal improvement on the CGIC.
‡‡ Statistical testing is not presented for the subgroup of patients who remained in phase 1 for 12 weeks.
§§ CGIC scores are as follows: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much
worse; and 7, very much worse. For the BPRS and the Neuropsychiatric Inventory, decreases in scores indicate decreases in the severity 
of symptoms.
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inferior to the other antipsychotic drugs was tested 
for superiority on the basis of a one-sided test 
with a P value of less than 0.025. Discontinuation 
of treatment for a specific reason was analyzed 
in the same way, except that the data for patients 
who discontinued treatment for a different rea-
son were censored at the time of discontinuation.
Patients who had a response to the assigned 
study drug were defined as those who were still 
in phase 1 and who had a CGIC score indicating 
at least minimal improvement at 12 weeks; all 
patients who had discontinued medications or 
who did not have minimal improvement on the 
CGIC scale were classified as not having a re-
sponse. Groups were compared with the use of 
a nonparametric analysis of covariance,30 strati-
fied according to the type of site and adjusted for 
the following baseline covariates: age, sex, MMSE 
score, and total BPRS score. Statistical testing 
followed the same strategy as for time to discon-
tinuation of treatment, with equivalence defined 
as a 95% CI of −0.20 to 0.20 for the difference 
between response rates.
The study was funded by the NIMH. The phar-
maceutical companies whose drugs were included 
in the study donated drug supplies; they were not 
involved in the design of the study, analyses, or 
interpretation of results. The authors and a pro-
tocol committee (see the Appendix) designed the 
trial. The site investigators gathered the data, 
and one of the authors analyzed the data. The 
manuscript was written by the authors, who 
vouch for the completeness and veracity of the 
data and data analyses.
R esult s
Patients, Caregivers, and Medication Doses
A total of 521 patients were screened and 421 
underwent randomization and received at least 
one dose of medication (Fig. 1). Eighty-two per-
cent of patients discontinued their initially as-
signed medication (i.e., during the 36-week fol-
low-up period).
Clinical characteristics of the patients are 
shown in Table 1. Fifty-seven percent required a 
level of care equivalent to that given in assisted-
living facilities, and 17% needed the equivalent of 
nursing home care.31 At baseline, 46% were re-
ceiving antihypertensive drugs, 24% cholesterol-
lowering drugs, 16% antiinflammatory drugs, and 
30% vitamin E.
Fifty-two percent of caregivers were spouses, 
and 33% were children or sons-in-law or daugh-
ters-in-law. The mean ages of caregivers were 73.5 
years for spouses and 51.2 years for children or 
their spouses; 71% were women.31 They spent a 
mean (±SD) of 5.2±4.0 hours per day in specific 
caregiving activities.32
The mean initially prescribed doses were 3.2 
mg of olanzapine per day, 34.1 mg of quetiapine 
per day, and 0.7 mg of risperidone per day. The 
last prescribed mean dose in phase 1 was 5.5 mg 
of olanzapine per day, 56.5 mg of quetiapine per 
day, and 1.0 mg of risperidone per day. The mean 
number of capsules prescribed was similar for all 
treatment groups: 0.7 large or 1.4 small capsules 
per day initially, and 1.1 large or 2.2 small cap-
sules per day for the last prescribed dose in 
phase 1.
Outcomes
There were no significant overall differences 
among treatment groups with regard to the time 
to discontinuation of treatment for any reason 
(Table 2 and Fig. 2A). The median time to discon-
tinuation of treatment ranged from 5.3 weeks with 
quetiapine to 8.1 weeks with olanzapine.
The median time to discontinuation of treat-
ment because of lack of efficacy was longer in the 
olanzapine group (22.1 weeks) and the risperi-
done group (26.7 weeks) than in the placebo group 
(9.0 weeks) (Table 2 and Fig. 2B). The hazard ratio 
for the discontinuation of treatment because of 
lack of efficacy was 0.51 (P<0.001) for olanza-
pine as compared with placebo, and 0.61 (P = 0.01) 
for risperidone. The time to discontinuation of 
treatment with quetiapine owing to lack of effi-
cacy (median, 9.1 weeks) did not differ signifi-
cantly from that for placebo. For the discontinu-
ation of treatment, olanzapine and risperidone 
were equivalent to each other (hazard ratio, 0.84; 
95% CI, 0.53 to 1.32), and olanzapine was sig-
nificantly superior to quetiapine (hazard ratio, 
0.63; 95% CI, 0.41 to 0.96; P = 0.02).
The time to discontinuation of treatment ow-
ing to intolerance of the study drug, adverse effects, 
or death favored placebo, with discontinuation 
rates of 24% for patients who received olanzapine, 
16% for patients who received quetiapine, and 18% 
for patients who received risperidone, as compared 
with 5% for patients who received placebo (Table 
2 and Fig. 2C). All three groups of patients who 
received an atypical antipsychotic drug were sig-
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nificantly more likely to discontinue treatment 
than were those who received placebo (hazard 
ratio for olanzapine, 4.32; 95% CI, 1.84 to 10.12; 
for quetiapine, 3.58; 95% CI, 1.44 to 8.91; and for 
risperidone, 3.62; 95% CI, 1.45 to 9.04).
At 12 weeks, 32% of patients in the olanza-
pine group had a response (i.e., a CGIC score in-
dicating at least minimal improvement with con-
tinued use of the phase 1 study medication), as 
compared with 26% in the quetiapine group, 29% 
in the risperidone group, and 21% in the placebo 
group; these rates were not significantly differ-
ent (P = 0.22). The overall rate of discontinuation 
of treatment at 12 weeks was 63%.
Adverse Events
There were no significant differences among the 
groups with regard to the proportion of patients 
who had at least one serious adverse event and the 
proportion who had any adverse event (Table 3). 
There were higher rates of parkinsonism or ex-
trapyramidal signs in the olanzapine and risperi-
done groups (12% in each) than in the quetiapine 
group (2%) or the placebo group (1%). Correspond-
ingly, the proportion of patients with a score of 
1 or more on the Simpson–Angus scale (on a 
scale of 0 to 4, with 1 indicating mild extrapy-
ramidal signs, and 4 the most severe signs) was 
higher with olanzapine (14%) and risperidone 
(11%) than with placebo (2%).
Sedation occurred more commonly with the 
three drugs (reported in 15 to 24% of patients) 
than with placebo (5%), and confusion or changes 
in mental status occurred more commonly with 
olanzapine (18%) and risperidone (11%) than with 
placebo (5%). Both cognitive disturbances and 
psychotic symptoms were more common with 
olanzapine (5% and 7%, respectively) than with 
the other medications or placebo (0 to 2%).
The body weight and body-mass index (BMI) 
of patients increased with antipsychotic drugs (by 
0.4 to 1.0 lb [0.18 to 0.45 kg] per month and 0.2 
BMI unit) and decreased slightly with placebo (by 
−0.9 lb [0.41 kg] per month and −0.2 BMI unit).
Prolactin levels at week 12 were markedly elevat-
ed in the risperidone group only.
Ten patients entered nursing homes during 
phase 1 (two patients receiving olanzapine, four 
patients receiving quetiapine, three patients re-
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Figure 2. Discontinuation of Treatment in Phase 1 According to Study Group.
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P Value (Overall 
Comparison)
Adverse event — no. (%)
Any serious adverse event† 14 (14) 17 (18) 9 (11) 19 (13) 0.35
Cerebrovascular accident or transient 
ischemic attack
2 (2) 1 (1) 1 (1) 1 (1) 0.92
Death 1 (1) 3 (3) 1 (1) 3 (2) 0.68
Any severe adverse event 17 (17) 24 (26) 12 (14) 21 (15) 0.11
Any adverse event 71 (71) 59 (63) 62 (73) 83 (58) 0.84
Parkinsonism or extrapyramidal 
signs
12 (12) 2 (2) 10 (12) 1 (1) <0.001
Gait disturbance 4 (4) 3 (3) 1 (1) 3 (2) 0.66
Sedation 24 (24) 21 (22) 13 (15) 7 (5) <0.001
Dizziness 6 (6) 6 (6) 4 (5) 9 (6) 0.96
Headache 5 (5) 1 (1) 5 (6) 2 (1) 0.10
Motor disturbance or dyskinesia 3 (3) 2 (2) 3 (4) 4 (3) 0.98
Cognitive disturbance 5 (5) 0 1 (1) 1 (1) 0.03
Seizures 3 (3) 1 (1) 0 0 0.07
Agitation or aggression 7 (7) 11 (12) 5 (6) 14 (10) 0.30
Psychotic symptoms 7 (7) 0 0 3 (2) 0.004
Confusion or mental-status change 18 (18) 6 (6) 9 (11) 7 (5) 0.03
Sleep disturbance 5 (5) 5 (5) 4 (5) 5 (4) 0.90
Depression 4 (4) 2 (2) 0 2 (1) 0.25
Anxiety 3 (3) 0 0 3 (2) 0.21
Fatigue or weakness 3 (3) 4 (4) 3 (4) 2 (1) 0.53
Falls, fractures, or injuries 17 (17) 7 (7) 10 (12) 21 (15) 0.16
Neurologic effects — no./total no. (%)‡
AIMS global severity score ≥2 1/73 (1) 2/55 (4) 2/64 (3) 1/96 (1) 0.62
Barnes Akathisia Rating Scale global 
score ≥3
1/73 (1) 1/55 (2) 0/64 0/96 0.33
Simpson–Angus Extrapyramidal Signs 
Scale mean score ≥1
10/73 (14) 5/54 (9) 7/64 (11) 2/94 (2) 0.03
P value for comparison with placebo 0.02 0.10 0.04
Specific reasons for discontinuation 
of treatment — no. (%)
Intolerability, adverse effects, or death 24 (24) 15 (16) 15 (18) 7 (5) <0.001
Sedation 6 (6) 3 (3) 3 (4) 1 (1) 0.10
Extrapyramidal signs 6 (6) 1 (1) 4 (5) 1 (1) 0.03
Dizziness 1 (1) 4 (4) 1 (1) 1 (1) 0.20
Cerebrovascular adverse event 1 (1) 1 (1) 1 (1) 2 (1) 1.0
Confusion 3 (3) 1 (1) 3 (4) 0 0.07
Other 7 (7) 5 (5) 3 (4) 2 (1) 0.13
Weight change from baseline to last 
observation
Weight gain >7% — no./total no. (%) 10/90 (11) 5/80 (6) 8/75 (11) 4/128 (3) 0.10
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P Value (Overall 
Comparison)
Weight change — lb/mo of treatment 1.0±0.4 0.4±0.6 0.7±0.4 −0.9±0.3 0.003
P value for comparison with 
placebo
0.001 0.03 0.008
Change in body-mass index from 
baseline to last observation
Change 0.3±0.1 0.2±0.1 0.3±0.1 −0.2±0.1 0.001
P value for comparison with 
placebo
0.001 0.02 0.001
Change in laboratory values from 
baseline to last observation§
Glucose — mg/dl 11.2±5.7 2.5±6.4 5.6±6.0 −1.2±5.0 0.28
Total cholesterol — mg/dl −11.3±4.6 −1.9±5.2 −7.5±4.9 −7.5±4.2 0.67
Triglycerides — mg/dl 20.1±10.2 16.0±11.5 1.3±10.9 11.9±9.4 0.40
Prolactin — mg/dl 4.1±3.6 −4.4±4.2 44.5±3.7 −4.6±3.4 <0.001
Electrocardiographic findings
Change in corrected QT interval from 
baseline to last observation — 
msec
−6.1±5.5 −0.1±4.4 5.1±4.7 4.8±4.9 0.27
Prolonged corrected QT interval — 
no./total no. (%)
0/37 3/31 (10) 1/32 (3) 4/52 (8) 0.19
New cataracts — no./total no. (%) 0/99 0/94 0/83 1/142 (1) 1.0
Medications added — no. (%)
Any psychotropic drug¶ 5 (5) 10 (11) 7 (8) 15 (11) 0.41
Antidepressant or antipsychotic agent 1 (1) 3 (3) 4 (5) 8 (6) 0.27
Benzodiazepine 3 (3) 8 (9) 3 (4) 7 (5) 0.35
Conventional antipsychotic agent 0 0 1 (1) 2 (1) 0.55
Atypical antipsychotic agent 0 1 (1) 1 (1) 4 (3) 0.32
Cholinesterase inhibitor 1 (1) 1 (1) 4 (5) 1 (1) 0.17
Antihypertensive agent 2 (2) 6 (6) 4 (5) 4 (3) 0.37
Gastrointestinal medication 6 (6) 1 (1) 2 (2) 5 (4) 0.28
* Plus–minus values are means ±SE. Comparisons of treatment groups are based on an overall test with 3 degrees of freedom and are presented
for descriptive purposes. For percentages, tests are based on a Poisson regression with adjustment for different exposure times or Fisher’s
exact test in the case of rates based on small numbers.33 Comparisons for continuous measures are based on an analysis of covariance
(ANCOVA) with adjustment for the duration of exposure. Laboratory values were tested with the use of ranked ANCOVA to account for 
skewed distributions.
† A serious adverse event is any adverse drug-related event that results in any of the following outcomes: death, a life-threatening condition, 
hospital admission or prolongation of a hospital stay, a persistent or clinically significant disability or incapacity, or a congenital anomaly 
or birth defect.34 The classification of an adverse event as severe was based on the judgment of the investigator.
‡ A global severity score of 2 or more on the Abnormal Involuntary Movement Scale (AIMS) indicates at least mildly abnormal movements. 
A score of 3 or more for the global clinical assessment of the Barnes Akathisia Rating Scale indicates at least moderate severity. A score 
of 1 or more on the Simpson–Angus Extrapyramidal Signs Scale indicates at least mild extrapyramidal signs (range, 0 to 4). For all three 
outcomes, percentages are based on the number of patients who did not meet the criteria at baseline and who underwent at least one post-
baseline measurement in phase 1.
§ Laboratory values are adjusted for duration of medication exposure. To convert values for blood glucose to millimoles per liter, multiply by
0.05551. To convert values for cholesterol to millimoles per liter, multiply by 0.02586. To convert values for triglycerides to millimoles per
 liter, multiply by 0.01129.
¶ This category includes antipsychotic agents, antiepileptic agents, hypnotics and sedatives, psychostimulants and nootropic agents, and anti-
depressants.
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Discussion
In this study, we randomly assigned patients with 
Alzheimer’s disease and psychosis, aggression, 
or agitation to placebo or one of three atypical 
antipsychotic medications. The median time to 
discontinuation of treatment for any reason ranged 
from 5 to 8 weeks, with no significant differences 
among the four groups. The study physicians dis-
continued the study drugs within 8 weeks after 
the start of treatment in about half the patients. 
This practice was consistent with the opinions of 
expert clinicians who have recommended dis-
continuing or switching antipsychotic treatment 
after 2 to 4 weeks in patients who are not bene-
fiting from it.5,8 The time to discontinuation of 
treatment, due to lack of efficacy, favored olan-
zapine and risperidone but was offset by the in-
creased rates of discontinuation of these drugs 
due to adverse events. Because the study was de-
signed to allow patients who discontinued a study 
medication in phase 1 to enter phase 2 and be 
randomly assigned to a different study drug, ex-
pectations that the phase 2 treatments might be 
more effective may have increased the likelihood 
of earlier discontinuation of treatment during 
phase 1.
The study physicians increased the initial med-
ication doses from an average of 1.4 small cap-
sules to an average of 2.2, equivalent to approxi-
mately 1.0 mg of risperidone, 5.5 mg of olanzapine, 
and 57.0 mg of quetiapine. The risperidone and 
olanzapine doses were both within the ranges 
recommended by experts5 and used in previous 
trials.9 The quetiapine dose, however, was half to 
a quarter that used in two nursing home trials.9
The protocol committee was unwilling to use 
a higher minimum starting dose of quetiapine 
or a larger incremental dose because of the pos-
sibility of excess sedation, but the committee ex-
pected that physicians would determine dosing 
individually for each patient. The rates of adverse 
events were similar among the drugs, however, 
so the apparent reluctance to increase the dose 
may have been related to observed adverse events 
or concern that adverse events would occur with 
higher doses of risperidone or olanzapine. Nev-
ertheless, the decision not to increase the dose in 
the face of an inadequate response limits some 
conclusions about efficacy and adverse effects.
Sedation was more likely with all of the anti-
psychotic drugs than with placebo and was par-
ticularly likely with olanzapine, which was also 
associated with increased confusion. Although 
worsening of cognition has been observed in other 
trials of antipsychotic medications for the treat-
ment of dementia,9 MMSE scores did not worsen 
in our trial. Extrapyramidal signs and symptoms 
with both risperidone and olanzapine were com-
mon reasons for the discontinuation of treat-
ment. The clinical significance of the expected 
hyperprolactinemia with risperidone is uncer-
tain. Patients gained weight with olanzapine and 
risperidone and lost weight with placebo; the 
possibility that antipsychotic drugs cause the 
metabolic syndrome in the elderly requires fur-
ther investigation.
The key enrollment criterion — the physician’s 
assessment that an antipsychotic drug was the 
appropriate pharmacologic therapy — helped to 
ensure clinical equipoise. The patient population 
was broad and representative in terms of age, 
race, ethnic group, level of disability, and extent 
of cognitive impairment. The level of psychopa-
thology was moderate to severe, which is similar 
to that in studies of patients in nursing homes.
Approximately 75% of the patients required a 
level of care at least equivalent to that given in 
assisted-living facilities.31 Most of the patients in 
our study required a level of care equivalent to 
that given in an assisted-living facility, and 17% 
needed the equivalent of nursing home care.31 
Washout from previous treatment and run-in 
periods were not used because of the patients’ 
acute clinical symptoms; instead, the study de-
sign allowed for rapid assignment and initiation 
of treatment to be consistent with clinical prac-
tice. Specifically, 14% percent of the patients 
were receiving antipsychotic medications within 
2 weeks before randomization (5% risperidone, 
4% haloperidol, 3% quetiapine, and 2% olan-
zapine). The use of cholinesterase inhibitors did 
not influence outcomes.
We used the discontinuation of treatment for 
any reason as a pragmatic measure of outcomes 
for individual patients rather than means for 
scores on rating scales because the discontinua-
tion of treatment incorporates the judgments of 
patients, caregivers, and clinicians regarding ef-
ficacy, safety, and tolerability and reflects thera-
peutic benefits in relation to undesirable effects. 
Previous trials compared mean scores on rating 
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scales according to group at the end of 6 to 12 
weeks without regard to tolerability and did not 
address the outcomes among individual patients. 
Our results are consistent with those of the few 
previous outpatient trials of atypical antipsychotic 
medications,9 which showed modest trends or 
no significant effects on symptom ratings.
Overall, the rates of discontinuation of treat-
ment among the four study groups ranged from 
77 to 85%. Although the differences among the 
groups may have been significant in a larger trial, 
our findings suggest that there is no large clini-
cal benefit of treatment with atypical antipsy-
chotic medications as compared with placebo.
Physicians were likely to switch medications 
quickly in the face of lack of efficacy or adverse 
effects. Although the atypical antipsychotic drugs 
were more effective than placebo, adverse effects 
limited their overall effectiveness, and their use 
may be restricted to patients who have few or no 
side effects and for whom benefits can be dis-
cerned. Clinicians, patients, and family members 
must consider both risks and benefits in order 
to optimize a patient’s care.
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